During AD progression, Aβ fragments and excitotoxic stimuli inhibit APC/C-Cdh1, leading to abnormal stabilization of PFKFB3, driving metabolic reprogramming and compromising the PPP’s antioxidant capacity (27–30). The gene discussed is APC; the disease is Alzheimer disease.